Investors’ Patience Is Being Tested Right Now By Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.

Stocks Info

Adaptimmune Therapeutics Plc ADR is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Adaptimmune Therapeutics Plc ADR is $78.06M. A total of 6.75 million shares were traded on the day, compared to an average of 1.62M shares.

In the most recent transaction, Norry Elliot sold 5,584 shares of ADAP for 0.58 per share on Jan 17 ’25. After the transaction, the Chief Medical Officer now owns 7,510 company shares. In a previous transaction on Jan 17 ’25, Lunger John sold 5,584 shares at 0.58 per share. ADAP shares that Chief Patient Supply Officer owns now total 7,510.

Among the insiders who sold shares, Bertrand William C JR disposed of 5,584 shares on Jan 17 ’25 at a per-share price of $0.58. This resulted in the Chief Operating Officer holding 7,510 shares of ADAP after the transaction. In another insider transaction, Rawcliffe Adrian sold 30,601 shares at $0.58 per share on Jan 17 ’25. Company shares held by the Chief Executive Officer now total 44,327.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ADAP has a high of $1.48 and a low of $0.20.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ADAP’s latest balance sheet shows that the firm has $369.58M in Cash & Short Term Investments as of fiscal 2021. There were $25.47M in debt and $62.54M in liabilities at the time. Its Book Value Per Share was $0.05, while its Total Shareholder’s Equity was $205.96M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ADAP is Buy with a score of 3.86.

Most Popular

Related Posts